Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Altimmune ( (ALT) ) just unveiled an update.
On September 25, 2025, Altimmune, Inc. held its 2025 Annual Meeting of Stockholders, where 58.6% of the company’s shares were represented. The meeting included elections for directors, ratification of Ernst & Young LLP as the independent accounting firm, an advisory vote on executive compensation, and a vote to authorize adjournment to solicit additional proxies. The results showed varying levels of support for directors and proposals, reflecting shareholder engagement and decision-making in corporate governance.
The most recent analyst rating on (ALT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.
Spark’s Take on ALT Stock
According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.
Altimmune’s overall stock score is primarily influenced by its financial challenges and bearish technical indicators. While the earnings call provided some positive developments in clinical trials and financial positioning, the ongoing losses and valuation concerns weigh heavily on the score.
To see Spark’s full report on ALT stock, click here.
More about Altimmune
Altimmune, Inc. operates in the biotechnology industry, focusing on the development of immunotherapeutic products for the treatment of liver disease, immune modulating therapies, and vaccines.
Average Trading Volume: 5,281,947
Technical Sentiment Signal: Sell
Current Market Cap: $346M
See more insights into ALT stock on TipRanks’ Stock Analysis page.